Targos Molecular Pathology GmbH and WuXi PharmaTech to Collaborate in Clinical Biomarker Services and Pathology Training in China

SHANGHAI, May 23, 2014 /PRNewswire/ -- Targos GmbH, a leader in clinical biomarker services, and WuXi PharmaTech (NYSE:WX), a leading pharmaceutical, biotechnology, and medical device R&D services company with operations in China and the United States, today announced a strategic biomarker collaboration.

Through this collaboration, Targos will provide know-how, services, and the quality standards to support WuXi's bioanalytical work for pharmaceutical customers. The collaboration will focus on the validation and analysis of clinical tissue biomarkers in cancer. Targos will also provide its internationally known training and education to support pathologists and histotechnologists in generating accurate, objective, and reproducible diagnostic results. By adding these new molecular pathology testing services from Targos, WuXi will provide customers with a comprehensive platform of services in soluble, cell, and tissue biomarkers.

"We are pleased to have found in WuXi a partner who shares our vision of offering customers the highest-quality biomarker services," said Dr. Thomas Henkel, CEO of Targos.

"This agreement with Targos advances WuXi's mission of offering our customers the broadest range of capabilities to support their drug development," said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech.

For further information please contact:

Targos Molecular Pathology GmbH

George L Kumar, PhD, MBA
Vice President of Marketing and Scientific Affairs
+ 1 425 777 6167
+ 49 151 46166805
[email protected] 

WuXi PharmaTech

Ronald Aldridge
Director of Investor Relations
+1-201-585-2048
[email protected]

Aaron Shi
Associate Director of Corporate Communications
+86-21-5046-4362
[email protected]

About Targos

Targos's core service business is to provide highly standardized development and application of clinical biomarkers for the international pharmaceutical and diagnostic industry. The company has supported more than 100 international clinical trials since 1999, which have led to the approval of several targeted therapies and IVDs for our customers. The expert team of on-site clinical pathologists operates in a professional environment of project management, logistics, data, and quality management. Targos also supports the introduction of new Companion Diagnostic assays into the market. Targos is a fully GCP-compliant central laboratory that is inspected by the U.S. Food and Drug Administration (FDA). Targos Molecular Pathology GmbH is accredited by the College of American Pathologists (CAP) and the Clinical Laboratory Improvement Amendments (CLIA). For more information, please visit http://www.targos-gmbh.de/.

About WuXi PharmaTech

WuXi PharmaTech (NYSE: WX) is a leading pharmaceutical, biotechnology, and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology, and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to help its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec.

SOURCE WuXi PharmaTech